PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30038842-9	2018	CONCLUSIONS: The results of this study and the preclinical and clinical evidence on the efficacy of combining HDACi with DNMTi strongly suggest that more studies are needed with this drug class combination in CTCL, particularly with the hydralazine-valproate scheme, which is safe, and these drugs are widely available and administered by oral route.	Hydralazine	237-248	TSPY like 2	Homo sapiens	209-213	
28277033-1	2017	OBJECTIVES: To evaluate the activity and safety of hydralazine and valproate (Transkrip) in cutaneous T-cell lymphoma (CTCL).	Hydralazine	51-62	TSPY like 2	Homo sapiens	119-123	
28277033-2	2017	METHODS: Previously untreated and progressive/refractory CTCL patients received hydralazine at 83 mg or 182 mg/day for slow and rapid acetylators respectively plus magnesium valproate at a total dose of 30 mg/Kg t.i.d daily in continuous 28-day cycles in this phase II study.	Hydralazine	80-91	TSPY like 2	Homo sapiens	57-61	
28277033-11	2017	CONCLUSION: The combination of hydralazine and valproate is safe, very well tolerated and effective in CTCL.	Hydralazine	31-42	TSPY like 2	Homo sapiens	103-107